UNCLASSIFIED

AD NUMBER

ADB253498

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Aug 99. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St, Fort Detrick, MD 21702-5012.

AUTHORITY

USAMRMC- Ft Detrick, MD, ltr. dtd24 Jul 2001.

THIS PAGE IS UNCLASSIFIED

AD_____

Award Number: DAMD17-99-1-9046

TITLE: Amplification of the Endothelin A Receptor Gene: A Potential Molecular Biomarker of Aggressive Prostate Cancer in African Americans

PRINCIPAL INVESTIGATOR: Joel B. Nelson, M.D.

CONTRACTING ORGANIZATION: Johns Hopkins University
Baltimore, MD 21287-2411

REPORT DATE: August 1999

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Aug 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000511 096

DTIC QUALITY INSPECTED 2

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9046
Organization: Johns Hopkins University

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Joel Nelson, M.D. 5/4/00

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	August 1999	Final (15 Feb 99 - 14 Aug 99)

4. TITLE AND SUBTITLE
Amplification of the Endothelin A Receptor Gene: A Potential Molecular Biomarker of Aggressive Prostate Cancer in African Americans

5. FUNDING NUMBERS
DAMD17-99-1-9046

6. AUTHOR(S)
Joel B. Nelson, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Johns Hopkins University
Baltimore, Maryland 21287-2411

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Distribution authorized to U.S. Government agencies only (proprietary information, Aug 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

12b. DISTRIBUTION CODE

13. ABSTRACT *(Maximum 200 words)*

Observations in our laboratory support the hypothesis that the endothelin axis is important in prostate carcinogenesis and progression, and that this pathway may be uniquely active in African American (AA) men, by virtue of potential amplification and overexpression of the endothelin receptor subtype A (ET_A). It is our hypothesis that the ET_A receptor is amplified in this patient population, and this contributes to a more aggressive disease course. In preliminary studies, Southern blot analysis of tumor DNA obtained from 5 African-American individuals was performed, using an ET_A cDNA probe: in every case, concentrations of ET_A DNA were greater in the tumor tissue (lymph node metastasis) compared to the corresponding normal tissue. The aims of this study were to determine whether the ET_A gene is amplified and differentially expressed in PCA from AA men, and if increased ET_A expression results in a more aggressive clinical course.

We found evidence for increased ET_A DNA in 20% of the samples studied, but we did not find convincing evidence for increased ET_A protein expression, using two complementary techniques. It is certainly possible a larger data set would include clear cases of ET_A overexpression at the DNA, RNA and protein levels.

14. SUBJECT TERMS
Prostate Cancer, Endothelin Receptors

15. NUMBER OF PAGES
10

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Limited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

__✓__ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



9/21/99

PI - Signature Date

Table of Contents

Standard Form (SF) 298, Report Documentation Page.....2

Foreword.....3

Table of Contents.....4

Introduction.....5

Body.....5-8

Key Research Accomplishments.....8

Reportable Outcomes.....8

Conclusions.....8

References.....9

Appendices.....9

Final Reports.....9

Introduction:

Observations in our laboratory support the hypothesis that the endothelin axis is important in prostate carcinogenesis and progression, and that this pathway may be uniquely active in African American (AA) men, by virtue of potential amplification and overexpression of the endothelin receptor subtype A (ET_A). It is our hypothesis that the ET_A receptor is amplified in this patient population, and this contributes to a more aggressive disease course. In preliminary studies, Southern blot analysis of tumor DNA obtained from 5 African-American individuals was performed, using an ET_A cDNA probe: in every case, concentrations of ET_A DNA were greater in the tumor tissue (lymph node metastasis) compared to the corresponding normal tissue. The aims of this study were to determine whether the ET_A gene is amplified and differentially expressed in PCA from AA men, and if increased ET_A expression results in a more aggressive clinical course.

Body:

Phase 1: Acquisition of Samples and Reagents (month 1)

In the initial phase of this project, we identified 10 normal/tumor pair samples from the prostate cancer tissue bank at the Brady Urological Institute for analysis. It was decided to first study a rather small and manageable set of samples to work out the details of the proposed analysis. Frozen sections (n=30) were obtained from each sample for immunohistochemistry and autoradiography. Additional sections were cut from the frozen tissue for DNA isolation. Genomic DNA was extracted using standard techniques. It was decided to not purchase an ET_A BAC clone until a tumor demonstrating ET_A amplification and overexpression was detected as a positive control.

Phase 2: Preliminary Experimentation Studying each tissue sample at multiple levels for ET_A expression (month 2-5)

As stated above, FISH analysis was not to be performed until a positive control, an ET_A over expressing tumor, could be identified.

Southern blot analysis was performed using the isolated genomic DNA extracted from normal/tumor pairs, digested with MspI, equally loaded and resolved on agarose gels. Following transfer to membranes, the blots were probed with an ET_A cDNA probe. We found evidence of increase ET_A DNA in two of the samples compared to their corresponding controls.

In stead of performing in situ hybridization, we acquired an ET_A-specific rabbit polyclonal antibody which was applied to each of the normal tumor pairs. In parallel to the ET_A staining, we studied expression of the other endothelin receptor, ET_B. Negative controls included omission of the antibody, nonspecific rabbit IgG, and preimmune rabbit serum. Positive controls included the media of blood vessels. As expected, we found expression of ET_A predominantly in the stromal component of the prostate gland with little to no expression in most of the benign epithelium. Areas of prostate cancer were also generally negative, although some ET_A staining was observed in areas of prostatic intra epithelial neoplasia (PIN). Interestingly, higher ET_B was noted in basal cells lining benign glands, but ET_B expression was lost in prostate cancer. Unfortunately, we also observed positive staining using preimmune rabbit serum in many of the areas read as positive (in the stromal component). At the time of this writing, we are adjusting antibody concentrations to limit this background.

On each section, autoradiography was also performed. Several attempts were required to obtain autoradiographs directly in the slides which were also stained with haematoxylon. Frozen

sections (20 μM) are incubated in one of the following solutions: total ET-1 binding (0.1 nM. ^{125}I-ET-1(label)), nonspecific binding (label + 1 μM. ET-1), total ET_B binding (label + 1 μM. BQ-123 or A-127722) and total ET_A binding (label + 0.1 μM. Sarafotoxin S6C or 1 μM. BQ-788). Rather than use the low resolution method previously described, we decided to use a high resolution emulsion technique. Similar to the findings using immunohistochemistry, we found the highest ET_A binding in areas of stroma: blood vessels provided a reliable internal control. We also observed ET_A binding in areas resembling PIN. We did not find increased ET_A binding in areas of infiltrating prostate cancer, even in the samples with increased ET_A DNA from the Southern blot analysis.

In summary, although we found evidence for increased ET_A DNA in 20% of the samples studied, we did not find convincing evidence for increased ET_A protein expression, using two complementary techniques. It is certainly possible a larger data set would include clear cases of ET_A overexpression at the DNA, RNA and protein levels. We found the amount of work required to fully analyze these 10 samples took nearly the entire time allotted. Despite an absence of data to support the initial hypothesis, we believe further investigation of ET_A expression in prostate cancer is warranted.

Phase 3: Data Analysis and Development of Grant Proposal Aims and Experiments (Month 6)

During the performance of this 6 month project, the DOD announced and submission was required for proposals directed towards prostate cancer. Given our preliminary data at the time of that request, we submitted a proposal to the DOD requesting additional time and funding to complete, in part, the studies outlined in the career development award. At the time of this

writing, the funding status of that proposal is unknown.

Key Research Accomplishments

- Increased ET_A DNA was observed in 20% of normal/tumor samples studied
- There was not a corresponding increase in ET_A protein expression in prostate cancer using immunohistochemistry and autoradiography
- ET_A protein expression was increased in areas of PIN

Reportable Outcomes

The only reportable outcome (drawing from the list provided) is the submission of a proposal (to the DOD) to study this question in more depth, with more samples, and over a longer time period.

Conclusions

We found evidence for increased ET_A DNA in 20% of the samples studied, we did not find convincing evidence for increased ET_A protein expression, using two complementary techniques. It is certainly possible a larger data set would include clear cases of ET_A overexpression at the DNA, RNA and protein levels. We found the amount of work required to fully analyze these 10 samples took nearly the entire time allotted. Despite an absence of data to support the initial hypothesis, we believe further investigation of ET_A expression in prostate cancer is warranted. Finally, the magnitude of the proposed project certainly exceeded the time allotted to such an

undertaking: put bluntly, in hindsight, this project could not have been performed in 6 months and requires a longer commitment of time and funding.

References

None

Appendices

None

Final Reports

There are no publications or meeting abstracts resulting from this preliminary project from any of the personnel receiving pay from the research effort (Joel B. Nelson, William Isaacs, Hong Zheng).

University of Pittsburgh Physicians

Department of Surgery

Part of
UPMC Health System

Urologic Surgery
Renal Transplantation

700 Kaufmann Building
3471 Fifth Avenue
Pittsburgh, PA 15213-3221
412-

September 21, 1999

Commander
U.S. Army Medical Research and Materiel Command
ATTN: MCMR-RMI-S
504 Scott Street
Fort Detrick, MD 21702-5012

RE: Final Report for Award Number DAMD17-99-1-9046

Dear Commander:

Enclosed please find a final report for the above named award. All the information included in this report is unpublished and distribution should be limited to the review by the Commander and appropriate staff. None of the information contained within this report should be made public.

Thank you for your patience and support.

Sincerely,

Joel B. Nelson, M.D.

Enclosures

DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

Received 7/24/2001

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports. Request the limited distribution statement for reports on the enclosed list be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

Encl